Harikrishnan, R, Naveen Kumar Panicker, Dr. Roy J. Mukkada, Dr. Ebin Thomas
{"title":"乌司替尼诱发水痘带状疱疹感染的病例报告","authors":"Harikrishnan, R, Naveen Kumar Panicker, Dr. Roy J. Mukkada, Dr. Ebin Thomas","doi":"10.36348/sjmps.2024.v10i07.011","DOIUrl":null,"url":null,"abstract":"Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn's disease, or moderate to severe ulcerative colitis (inflammatory bowel disease). Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). Although rare, the emergence of severe infections or exacerbation/reactivation of existing infections (bacterial, mycobacterial, fungal, viral) is possible for Ustekinumab. We report a case of a 29-year-old female patient who was prescribed Ustekinumab for Crohn’s disease management. After the commencement of the drug for two doses she developed Varicella pneumonia with ARDS which was subsequently managed.","PeriodicalId":508857,"journal":{"name":"Saudi Journal of Medical and Pharmaceutical Sciences","volume":" 22","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Case Report on Ustekinumab-Induced Varicella Zoster Infection\",\"authors\":\"Harikrishnan, R, Naveen Kumar Panicker, Dr. Roy J. Mukkada, Dr. Ebin Thomas\",\"doi\":\"10.36348/sjmps.2024.v10i07.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn's disease, or moderate to severe ulcerative colitis (inflammatory bowel disease). Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). Although rare, the emergence of severe infections or exacerbation/reactivation of existing infections (bacterial, mycobacterial, fungal, viral) is possible for Ustekinumab. We report a case of a 29-year-old female patient who was prescribed Ustekinumab for Crohn’s disease management. After the commencement of the drug for two doses she developed Varicella pneumonia with ARDS which was subsequently managed.\",\"PeriodicalId\":508857,\"journal\":{\"name\":\"Saudi Journal of Medical and Pharmaceutical Sciences\",\"volume\":\" 22\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Saudi Journal of Medical and Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36348/sjmps.2024.v10i07.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Medical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36348/sjmps.2024.v10i07.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Case Report on Ustekinumab-Induced Varicella Zoster Infection
Ustekinumab is a human monoclonal antibody typically used to treat moderate to severe plaque psoriasis, psoriatic arthritis, moderate to severe Crohn's disease, or moderate to severe ulcerative colitis (inflammatory bowel disease). Ustekinumab mediates the body's T-cell response by acting as an antagonist against interleukin-12 (IL12) and interleukin-23 (IL23). Although rare, the emergence of severe infections or exacerbation/reactivation of existing infections (bacterial, mycobacterial, fungal, viral) is possible for Ustekinumab. We report a case of a 29-year-old female patient who was prescribed Ustekinumab for Crohn’s disease management. After the commencement of the drug for two doses she developed Varicella pneumonia with ARDS which was subsequently managed.